Personalized DC vaccine hits safety bar in 11-patient glioblastoma trial
The phase 1b abstract shows median PFS of 16.2 months and no OS reached, but the safety-only design and n=11 leave efficacy unproven.
Executive Summary
- A phase 1b abstract for ZSNeo-DC, a personalized neoantigen-pulsed dendritic cell vaccine, met its safety-primary endpoint in 11 newly-diagnosed glioblastoma patients, with AEs mostly grade 1 or 2 and only two treatment-related febrile events Press ReleasePress ReleaseJul 4, 2026.
- Secondary data showed median progression-free survival of 16.2 months, median overall survival not reached, and a 100% one-year survival rate, figures that read favorably against historical glioblastoma outcomes but come from an uncontrolled 11-patient cohort Press ReleasePress ReleaseJul 4, 2026.
- The single-arm, open-label design and small sample mean the survival numbers are exploratory, not a controlled demonstration of efficacy, and no p-values or confidence intervals accompany the reported figures Press ReleasePress ReleaseJul 4, 2026.
- No AppliedXL model read exists for this event, so there is no pre-event probability to grade the outcome against.
- The authors say the data support phase 2 evaluation in expanded cohorts, making the open question whether a controlled, larger trial confirms the immune and survival signals seen here Press ReleasePress ReleaseJul 4, 2026.
The result
Beijing Tiantan Hospital, sponsoring NCT04968366 with collaborator ZhongSheng BioTech Inc., disclosed phase 1b results for ZSNeo-DC in an abstract published July 4, 2026 Press ReleasePress ReleaseJul 4, 2026. The trial's registered primary endpoint was the incidence and severity of treatment-emergent adverse events, tracked from the first vaccination through eight weeks after the last dose. The abstract reports the treatment "was well tolerated, with AEs predominantly grade 1 or 2; only two grade-1/2 febrile AEs were recorded as treatment-related" Press ReleasePress ReleaseJul 4, 2026. That result clears the safety bar the trial was designed to test, though the design says nothing about efficacy on its own.
The efficacy signal
Beyond safety, the secondary endpoints reported median progression-free survival of 16.2 months and a median overall survival that had not been reached at the time of analysis, with a 12-month overall survival rate of 100% from the date of surgery Press ReleasePress ReleaseJul 4, 2026. Peripheral neoantigen-specific immune response rose a median of 7.2-fold after the third vaccination and 10.3-fold after the fifth, with individual patients showing increases as high as 284.7-fold and 507.0-fold Press ReleasePress ReleaseJul 4, 2026. The authors also report that markers of T-cell activation and receptor-repertoire diversity increased after vaccination and correlated positively with both immune response and progression-free survival Press ReleasePress ReleaseJul 4, 2026. These are descriptive, hypothesis-generating findings, not statistically powered comparisons: no p-values or confidence intervals accompany them in the disclosed abstract.
What the design can and cannot show
The trial enrolled 11 patients in a single-arm, open-label design with no comparator arm, which means it cannot establish that ZSNeo-DC caused the observed survival outcomes versus standard care alone Press ReleasePress ReleaseJul 4, 2026. The registry shows the primary completion date slipped twice, from August 2022 to December 2023 and then to March 2024, a cumulative delay of 608 days, and the trial's status moved from Recruiting to Active, not recruiting, in February 2024 without enrollment growth beyond a one-patient increase from 10 to 11. No results have been posted on ClinicalTrials.gov. Beijing Tiantan Hospital has an 8-trial, 100% completion track record, which supports operational credibility even as the protocol-stability tool flags the trial as "Unstable" based on the frequency of registry changes.
What it changes
No AppliedXL model probability was generated for this trial ahead of the abstract, and the readout-date forecast tool returned no prediction row for NCT04968366, so there is no forward-looking model read to compare against the outcome. No regulatory designations, such as Breakthrough Therapy, Fast Track, or Orphan Drug status, have been recorded for the program, and no named direct competitor or nearest-precedent personalized neoantigen-DC vaccine trial in glioblastoma appears in the dossier. The authors' own framing, that the data "support phase 2 evaluation in expanded cohorts," sets the bar for what would need to happen next: a larger, ideally controlled trial to test whether the safety and exploratory efficacy signals hold Press ReleasePress ReleaseJul 4, 2026.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.